Immunization with recombinant Varicella-Zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs

Journal of Virology

Volumn 69, Issue 12, 1995, Pages 8109-8113

  Heineman, Thomas C ^a,c   Connelly, Beverly L ^b   Bourne, Nigel ^b   Stanberry, Lawrence R ^b   Cohen, Jeffrey ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ARTICLE; DISEASE SEVERITY; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX VIRUS 2; IMMUNIZATION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS;

EID: 0028971199     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.69.12.8109-8113.1995     Document Type: Article

References (32)

1. Arvin, A. M., S. Solem, C. Koropchak, E. Kinney-Thomas, and S. Paryani. 1987. Humoral and cellular immunity to varicella-zoster virus glycoprotein gpI and to a non-glycosylated protein, p170, in the strain 2 guinea pig. J. Gen. Virol. 68:2449-2454.
2. Herman, P. W., T. Gregory, D. Crase, and L. A. Lasky. 1985. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Science 227:1490-1492.
3. Bernstein, D. I., L. R. Stanberry, C. J. Harrison, J. C. Kappes, and M. G. Myers. 1986. Antibody response, recurrent patterns, and subsequent herpes simplex virus type 2 (HSV-2) reinfection following initial HSV-2 infection of guinea pigs: effects of acyclovir. J. Gen. Virol. 67:1601-1612.
4. Campadelli-Fiume, G., and F. Serafini-Cessi. 1985. Processing of the oligosaccharide chains of herpes simplex virus type 1 glycoproteins, p. 357-382. In B. Roizman (ed.), The herpesviruses. Plenum Press, New York.
5. Cohen, G. H., M. Katze, C. Hydrean-Stern, and R. J. Eisenberg. 1979. Type-common CP-1 antigen of herpes simplex virus is associated with a 59,000-molecular weight envelope glycoprotein. J. Virol. 27:172-181.
6. Cohen, J. I., and K. E. Seidel. 1993. Generation of varicella-zoster virus (VZV) and viral mutants from cosmids: VZV thymidylate synthetase is not essential for replication in vitro. Proc. Natl. Acad. Sci. USA 90:7376-7380.
7. Cohen, J. I., and K. E. Seidel. 1994. Absence of varicella-zoster virus (VZV) glycoprotein V does not alter growth of VZV in vitro or sensitivity to heparin. J. Gen. Virol. 75:3087-3093.
8. Cohen, J. I., and K. E. Seidel. 1994. Varicella-zoster virus (VZV) open reading frame 10 protein, the homolog of the essential herpes simplex virus protein VP16, is dispensable for VZV replication in vitro. J. Virol. 68:7850-7858.
9. Cohen, J. I., and K. E. Seidel. 1995. Varicella-zoster virus ORF1 encodes a membrane protein that is dispensable for growth of VZV in vitro. Virology 206:835-842.
10. Davison, A. J., and J. E. Scott. 1986. The complete DNA sequence of varicella-zoster virus. J. Gen. Virol. 67:1759-1816.
11. Fuller, A. O., and W. L. Lee. 1992. Herpes simplex virus type 1 entry through a cascade of virus-cell interactions requires different roles of gD and gH in penetration. J. Virol. 66:5002-5012.
12. Heineman, T. C., and J. I. Cohen. 1994. Deletion of the varicella-zoster virus large subunit of ribonucleotide reductase impairs growth of virus in vitro. J. Virol. 68:3317-3323.
13. Heineman, T. C., and J. I. Cohen. 1995. The varicella-zoster virus (VZV) open reading frame 47 (ORF47) protein kinase is dispensable for viral replication and is not required for phosphorylation of ORF63 protein, the VZV homolog of herpes simplex virus ICP22. J. Virol. 69:7368-7371.
14. Heineman, T. C., and J. I. Cohen. Unpublished data.
15. Johnson, R. M., D. W. Lancki, F. W. Fitch, and P. G. Spear. 1990. Herpes simplex virus glycoprotein D is recognized as antigen by CD4+ and CD8+ T lymphocytes from infected mice: characterization of T cell clones. J. Immunol. 145:702-710.
16. Kohl, S., N. C. Strynadka, R. S. Hodges, and L. Pereira. 1990. Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B. J. Clin. Invest. 86:273-278.
17. Ligas, M. W., and D. C. Johnson. 1988. A herpesvirus mutant in which glycoprotein D sequences are replaced by β-galactosidase sequences binds to but is unable to penetrate cells. J. Virol. 62:1486-1494.
18. Lowe, R. S., P. M. Keller, B. J. Keech, A. J. Davison, Y. Whang, A. J. Morgan, E. Kieff, and R. W. Ellis. 1987. Varicella-zoster virus as a live vector for the expression of foreign genes. Proc. Natl. Acad. Sci. USA 84:3896-3900.
19. McGeoch, D. J., H. W. Moss, D. McNab, and M. C. Frame. 1987. DNA sequence and genetic content of the HindIII 1 region in the short unique component of the herpes simplex virus type 2 genome: identification of the gene encoding glycoprotein G, and evolutionary comparisons. J. Gen. Virol. 68:19-38.
20. Muggeridge, M. I., S. R. Roberts, V. J. Isola, G. H. Cohen, and R. J. Eisenberg. 1990. Herpes simplex virus, p. 235-241. In M. V. H. Van Regenmortel and A. R. Neurath (ed.), Immunochemistry of viruses II: the basis for serodiagnosis and vaccines. Elsevier, Amsterdam.
21. Myers, M. G., B. Connelly, and L. Stanberry. 1991. Varicella in hairless guinea pigs. J. Infect. Dis. 163:746-751.
22. Myers, M. G., and B. L. Connelly. 1992. Animal models of varicella. J. Infect. Dis. 166 (Suppl. 1):S48-S50.
23. Shiraki, K., Y. Hayakawa, H. Mori, J. Namazue, A. Takamizawa, I. Yoshida, K. Yamanishi, and M. Takahashi. 1991. Development of immunogenic recombinant Oka varicella vaccine expressing hepatitis B virus surface antigen. J. Gen. Virol. 72:1393-1399.
24. Stanberry, L. R. 1990. Subunit viral vaccines: prophylactic and therapeutic use, p. 309-341. In L. Aurelian (ed.), Herpesviruses, the immune system and AIDS. Kluwer Academic, Norwell.
25. Stanberry, L. R., D. I. Bernstein, R. L. Burke, C. Pachl, and M. G. Myers. 1987. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J. Infect. Dis. 155:914-920.
26. Stanberry, L. R., R. L. Burke, and M. G. Myers. 1988. Herpes simplex virus glycoprotein treatment of recurrent genital herpes. J. Infect. Dis. 157:156-163.
27. Stanberry, L. R., E. R. Kern, J. T. Richard, T. M. Abbott, and J. C. Overall, Jr. 1982. Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J. Infect. Dis. 146:397-404.
28. Straus, S. E., L. Corey, R. L. Burke, B. Savarese, G. Barnum, P. R. Krause, R. G. Kost, J. L. Meier, R. Sekulovich, S. F. Adair, and C. L. Dekker. 1994. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343:1460-1463.
29. Straus, S. E., B. Savarese, M. Tigges, A. G. Freifeld, P. R. Krause, D. M. Margolis, J. L. Meier, D. P. Paar, S. F. Adair, D. Dina, C. L. Dekker, and R. L. Burke. 1993. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J. Infect. Dis. 167:1045-1052.
30. Takahashi, M. 1992. Current status and prospects of live varicella vaccine. Vaccine 10:1007-1014.
31. Wachsman, M., L. Aurelian, C. C. Smith, B. R. Lipinskas, M. E. Perkins, and E. Paoletti. 1987. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. J. Infect. Dis. 155:1188-1197.
32. Watson, R. J. 1983. DNA sequence of the herpes simplex virus type 2 glycoprotein D gene. Gene 26:307-312.